title: Predictors of Human Papillomavirus Vaccine Completion Among Female and Male Vaccine Initiators in Family Planning Centers.
abstract: OBJECTIVE
  We estimated human papillomavirus (HPV) vaccine series completion and examined predictors of completion among adolescents and young adults in a large family planning network.
  
  
  METHODS
  Our retrospective cohort study of vaccine completion within 12 months and time to completion used electronic health record data from 119 Planned Parenthood health centers in 11 US states for 9648 patients who initiated HPV vaccination between January 2011 and January 2013.
  
  
  RESULTS
  Among vaccine initiators, 29% completed the series within 12 months. Patients who were male, younger than 22 years, or non-Hispanic Black or who had public insurance were less likely to complete within 12 months and completed more slowly than their counterparts. Gender appeared to modify the effect of public versus private insurance on completion (adjusted hazard ratio = 0.76 for women and 0.95 for men; relative excess risk due to interaction = 0.41; 95% confidence interval = 0.09, 0.73).
  
  
  CONCLUSIONS
  Completion was low yet similar to previous studies conducted in safety net settings.
authors.affiliation: The authors are with Planned Parenthood Federation of America, New York, NY.
authors.forename: Hannah R
authors.initials: HR
authors.lastname: Simons
authors.affiliation: The authors are with Planned Parenthood Federation of America, New York, NY.
authors.forename: Zoe D
authors.initials: ZD
authors.lastname: Unger
authors.affiliation: The authors are with Planned Parenthood Federation of America, New York, NY.
authors.forename: Priscilla M
authors.initials: PM
authors.lastname: Lopez
authors.affiliation: The authors are with Planned Parenthood Federation of America, New York, NY.
authors.forename: Julia E
authors.initials: JE
authors.lastname: Kohn
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D010349:Patient Compliance / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D012737:Sex Factors; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines